Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy

John R. Crossen, David L. Goldman, Suellen A. Dahlborg, Edward Neuwelt

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The risk of neurotoxicity was evaluated in eight consecutive patients with non-acquired immunodeficiency syndrome (AIDS) primary central nervous system lymphoma who had survived disease free for more than 1 year after completion of treatment with osmotic opening of the blood-brain barrier and chemotherapy (methotrexate, cytoxan, procarbazine, and decadron). Trends in neuropsychological assessment results between baseline and follow-up (1 to 7 years) were analyzed for all eight nonradiated survivors. This serial assessment design addressed the specific issue of neurotoxic risk potential of treatment, when confounding factors of tumor persistence/recurrence and cranial irradiation were ruled out. Follow-up results of an extensive battery of tests to assess higher cortical function provided evidence of the safety of chemotherapy protocol with the blood-brain barrier disruption. These findings stand in contrast to well-known cognitive risks associated with cranial radiotherapy. Long-term follow-up suggests that chemotherapy can be given in conjunction with osmotic opening of the blood-brain barrier in nonradiated patients without cognitive manifestations of neurotoxicity.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalNeurosurgery
Volume30
Issue number1
StatePublished - 1992

Fingerprint

Blood-Brain Barrier
Lymphoma
Central Nervous System
Outcome Assessment (Health Care)
Drug Therapy
Procarbazine
Cranial Irradiation
Neurobehavioral Manifestations
Methotrexate
Cyclophosphamide
Dexamethasone
Survivors
Radiotherapy
Safety
Recurrence
Therapeutics
Neoplasms

Keywords

  • Blood-brain barrier
  • Brain cancer
  • Neuropsychological assessment
  • Primary central nervous system lymphoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. / Crossen, John R.; Goldman, David L.; Dahlborg, Suellen A.; Neuwelt, Edward.

In: Neurosurgery, Vol. 30, No. 1, 1992, p. 23-29.

Research output: Contribution to journalArticle

@article{37a55cc58ebe4dfaa075731a08c58cd4,
title = "Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy",
abstract = "The risk of neurotoxicity was evaluated in eight consecutive patients with non-acquired immunodeficiency syndrome (AIDS) primary central nervous system lymphoma who had survived disease free for more than 1 year after completion of treatment with osmotic opening of the blood-brain barrier and chemotherapy (methotrexate, cytoxan, procarbazine, and decadron). Trends in neuropsychological assessment results between baseline and follow-up (1 to 7 years) were analyzed for all eight nonradiated survivors. This serial assessment design addressed the specific issue of neurotoxic risk potential of treatment, when confounding factors of tumor persistence/recurrence and cranial irradiation were ruled out. Follow-up results of an extensive battery of tests to assess higher cortical function provided evidence of the safety of chemotherapy protocol with the blood-brain barrier disruption. These findings stand in contrast to well-known cognitive risks associated with cranial radiotherapy. Long-term follow-up suggests that chemotherapy can be given in conjunction with osmotic opening of the blood-brain barrier in nonradiated patients without cognitive manifestations of neurotoxicity.",
keywords = "Blood-brain barrier, Brain cancer, Neuropsychological assessment, Primary central nervous system lymphoma",
author = "Crossen, {John R.} and Goldman, {David L.} and Dahlborg, {Suellen A.} and Edward Neuwelt",
year = "1992",
language = "English (US)",
volume = "30",
pages = "23--29",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy

AU - Crossen, John R.

AU - Goldman, David L.

AU - Dahlborg, Suellen A.

AU - Neuwelt, Edward

PY - 1992

Y1 - 1992

N2 - The risk of neurotoxicity was evaluated in eight consecutive patients with non-acquired immunodeficiency syndrome (AIDS) primary central nervous system lymphoma who had survived disease free for more than 1 year after completion of treatment with osmotic opening of the blood-brain barrier and chemotherapy (methotrexate, cytoxan, procarbazine, and decadron). Trends in neuropsychological assessment results between baseline and follow-up (1 to 7 years) were analyzed for all eight nonradiated survivors. This serial assessment design addressed the specific issue of neurotoxic risk potential of treatment, when confounding factors of tumor persistence/recurrence and cranial irradiation were ruled out. Follow-up results of an extensive battery of tests to assess higher cortical function provided evidence of the safety of chemotherapy protocol with the blood-brain barrier disruption. These findings stand in contrast to well-known cognitive risks associated with cranial radiotherapy. Long-term follow-up suggests that chemotherapy can be given in conjunction with osmotic opening of the blood-brain barrier in nonradiated patients without cognitive manifestations of neurotoxicity.

AB - The risk of neurotoxicity was evaluated in eight consecutive patients with non-acquired immunodeficiency syndrome (AIDS) primary central nervous system lymphoma who had survived disease free for more than 1 year after completion of treatment with osmotic opening of the blood-brain barrier and chemotherapy (methotrexate, cytoxan, procarbazine, and decadron). Trends in neuropsychological assessment results between baseline and follow-up (1 to 7 years) were analyzed for all eight nonradiated survivors. This serial assessment design addressed the specific issue of neurotoxic risk potential of treatment, when confounding factors of tumor persistence/recurrence and cranial irradiation were ruled out. Follow-up results of an extensive battery of tests to assess higher cortical function provided evidence of the safety of chemotherapy protocol with the blood-brain barrier disruption. These findings stand in contrast to well-known cognitive risks associated with cranial radiotherapy. Long-term follow-up suggests that chemotherapy can be given in conjunction with osmotic opening of the blood-brain barrier in nonradiated patients without cognitive manifestations of neurotoxicity.

KW - Blood-brain barrier

KW - Brain cancer

KW - Neuropsychological assessment

KW - Primary central nervous system lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0026527243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026527243&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 23

EP - 29

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -